CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Advanced Strategies for Achieving IGF-I Control in Acromegaly CME
Co Directors: Michael O. Thorner, MB, BS, DSc., MACP; Peter J. Trainer, MD, BSc, FRCP; Faculty: Ian M. Holdaway, MD, FRACP, BMed Sc; Arial L. Barkan, MD; Mary Lee Vance, MD; William Drake, MD; David R. Clemmons, MD
Disclosures

Release Date: September 24, 2003; Valid for credit through September 24, 2004

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Advanced Strategies for Achieving IGF-I Control in Acromegaly " symposium held at the Philadelphia Marriott in Philadelphia, PA on June 18, 2003.

Contents of This CME Activity
This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Importance of Controlling GH/IGF Axis in Acromegaly
    by Ian M. Holdaway, MD, FRACP, BMed Sc
    Mortality in Acromegaly
    Causes of Death
    Factors Influencing Mortality
    Growth Hormone as a Predictor of Mortality
    Growth Hormone and Surgical Treatment
    IGF-I as a Marker for Mortality
    Assessing Comparison Studies
    IGF-I and the Complications of Acromegaly

  2. Relative Merits of GH and IGF-I in Diagnosis of Acromegaly
    by Arial L. Barkan, MD
    Pathogenesis and Diagnosis of Acromegaly
    Biochemical Targets in Acromegaly
    Growth Hormone in Assessment of Acromegaly
    IGF-I in Assessment of Acromegaly
    IGF-I or Growth Hormone for Assessment in Acromegaly?
    Diagnosis and Surveillance of Acromegaly?

  3. Pegvisomant Therapy for Acromegaly
    by Mary Lee Vance, MD
    Pegvisomant: Clinical Use
    Clinical Studies
    Pegvisomant: Effect on IGF-I
    Pegvisomant: Effect on Growth Hormone and IGF-I
    Pegvisomant: Effect on Glucose, Tumor Size
    Pegvisomant: Patient Management
    Pegvisomant: Summary and Conclusions

  4. Metabolic Impact of Medical Therapy of Acromegaly
    by William Drake, MD
    Metabolic Markers for Acromegaly
    The Growth Hormone/IGF-I Axis
    Insulin Resistance/Glucose Tolerance in Acromegaly
    Octreotide Therapy and Insulin/Glucose Ratio
    Pegvisomant and Glucose Tolerance
    Converting to Pegvisomant From Octreotide LAR
    Conclusions

  5. Treatment Algorithm for Acromegaly in 2003
    by David R. Clemmons, MD
    Treatment Goals and Therapeutic Options
    Therapeutic Options: Surgery
    Therapeutic Options: Radiotherapy
    Medical Therapy
    Medical Therapy: Somatostatin Analogs
    Medical Therapy: Pegvisomant
    Treatment Algorithm

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, The Endocrine Society, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2003 The Endocrine Society.
Pfizer
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.